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The relationships between DMBA-induced mammary
cancer, polyunsaturat~d fatty_ acids, -and PGE2_ as well as
the effect of prostaglandin inhibitor indomethacin (IM).
were examined.

Those animals fed a diet containing 20%

corn oil (HF) exhibited higher tumor burden, more rapid
tumor growth and higher PGE2 levels than the rats fed 4%
corn oil (LF).

The addition of IM to the animals

drinking water in the HF group caused a reduction in
PGE2 levels.
tumor growth.

However, IM had little effect on their
The addition of IM to the LF group

reduced the percentage of tumor bearing rats by 23% to
that of the LF group.

Yet, the average tumor volume per

rat was higher in all groups that received IM.
Therefore, the conditions of this research demonstrated
a mild role of PGE2 in the promotion of tumorigenesis in
those groups not given IM treatment.
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INTRODUCTION

Investigations have identified a number of risk
factors for the development of breast cancer, including
early age at menarche, late age at first child birth,
late age at menopause, and a family history of breast
cancer.

However, these factors do not explain the

marked differences in breast cancer among women of
different ethnic background around the world (·l) .

The

fact that one out of 10 American women develope breast
cancer (2), and this type of cancer is the most frequent
cause of cancer related death in these women brought
about many studies in the last decade in the possible
causes for the discrepancies (3).

It was quickly

determined that dietary fat played a major role.

The

United States has one of the highest dietary fat intakes
per capita in the world and it has been estimated that
the average American diet is composed of 20% fat (4).
It has been shown that diet effects mammary
tumors at two levels--the rate at which they form and
the rate at which they grow (3).

Yet, the mechanisms by

which these rates are effected are still unclear.
Several animal studies using a variety of both
l
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spontaneous, translatable, and induced mammary tumors
have demonstrated a direct correlation between a high
fat diet and the growth of mammary tumors (4-17).
A possible mechanism being widely studied is the
role of prostaglandins.

Prostaglandins are lipid

derived, therefore it was assumed that an increase in
dietary fat would lead to an increase in prostaglandin
production.

Several laboratories have demonstrated this

concept (4-31).

It was through the use of prostaglandin

inhibitors that a correlation between a reduction in the
level of prostaglandins and tumor growth was first
exhibited in several studies (4,5,11) while a study by
Feldman and Hilf was not as successful (21).

Diet and Cancer,
The accepted mechanism for cancer development is·
that the cancer is first initiated by some factor (i.e.
chemical, ra~iation, virus) followed by a longer term
promotional phase.

Lipids have been suggested to be a

tumor_ promoter.
After it.was demonstrated that a high fat diet
enhanced tumorigenesis, further study was needed to
determine if some types of lipid were more effective at
enhancing tumor growth than others.

There appeared to

be a tendency for diets high in polyunsaturated fat to
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have higher tumor yields than saturated fat diets (1).
It was further observed that a combination of a large
amount of polyunsaturated fat with a small amount of
saturated fat produced more mammary tumors than either
source of fat (1).

In general, diets rich in

unsaturated fats (e.g. most vegetable oils) are more
efficacious than diets rich in saturated fats (e.g, many
animal fats) in the enhancement of the promotional stage
of mammary tumorigenesis (9).

Recent studies suggest

that diets rich in saturated fatty acids, in contrast to
unsaturated fatty acids, may be more important in the
initiation stage of this tumorigenic process (9).
Evidence now indicates that only a small amount of
polyunsaturated fat is required to enhance the yield of
mammary tumors.

As little as 3% polyunsaturated fat

when fed in a high saturated fat diet promoted tumor
development as effectively as a diet containing four
times as much (10).
In a study by Hillyard and Abraham on the
cellular elavation of tumors, it was determined that
there was no difference in Gl,S,G2,M, or the total cell
cycle time between the two diets.

The same study

reported that only about 40% of the tumor cells were
dividing at any given time, and there was probably a
constant interchange between the proliferating and
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quiescent cell populations (15).

These results show

that the differe~ce in tumor weights between the two
groups could not be accounted for by an effect on the
fraction of cells dividing or a difference in cell cycle
time.

The size difference in the tumors were determined

by the balance between tumor cell lysis and those tumor
cells proliferating (15).

The tumor cells provided a

diet of saturated fat die faster than those provided a
diet of polyunsaturated fat.

Another.possible

explanation is that the· cells promoted by a
polyunsaturated fat diet started growing earlier.
is not the case.

This

It was determined by Hillyard and

Abraham that raptd tumor growth occurred at the same
time if the animal received a fat free or
polyunsaturated fat diet (6).

The increase in

polyunsaturated fat increases fluidity of the cell
membrane, but this does not influence the susceptibility_
of the target cells to complement~mediated lysis (14).
,Corn oil, contains_60% linoleic acid (11).
Linoleic acid is the only pure polyunsaturated fatty
acid known to promote mammary tumor growth (13).

Rats

with diets containing either 0.5% or 20% corn oil showed
a tumor incidence of 20 to 28% with the low fat and 72
to 76% with the high fat diet (12).

Fish oil

which also contains polyunsaturated fatty acids doesn't
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have similar tumorigenic effects ( 10) .•

Another fatty

acid isolated from the seed oil of the columbine, is an
18-carbon fatty acid with three double bonds.

It

contains two cis bonds at carbons 9 and 12 similar to
linoleic acid and, in addition,. it possesses a double
bond with a transconfiguration at the 5 position (13).
This fatty acid with its configuration so similar to
linoleic acid

would be expected to enhance tumor growth

to some extent but it does not. Rats fed this fatty acid
do not convert it to linoleic acid to any appreciable
degree (13).

Stearate which contains 18 carbons but is

saturated and oleate which contains a single double bond
in the cis 9 position also do not enhance tumor growth
(13).

It was concluded from this data that 18 carbon

fatty acids require two double bonds, as does linoleic
acid, to be effective promoters.
work from independent laboratories have shown an
increase in the level of free fatty acids in tumor
bearing animals and most of which is believed to be
utilized by the tumor as a source of energy (7).

The

cholesterol levels, free and esterified, we~e also
increased in the plasma of tumor bearing rats (7).

A

later study determined that the amount of linoleic acid
in the total serum lipids closely reflects that of the
diet (5).

However this was not unexpected since
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linoleic acid is an essential fatty acid.

Another study

demonstrated that the total serum lipid levels were
higher ih animals fed

a low fat diet.while it was the

reverse in the high fat diet.

A possible explanation is

that a high fat diet would inhibit endogenous lipid
synthesis (5).

rt is well known that most animals

convert linoleic acid to dihomo-~-linolate and
arachidonate (see Fig. 1), precursors of prostaglahdins
( 13) •

Al though. die_tary linoleic acid correlates closely

with total serum and tumor linoleic acid levels it does
not equate with its metabolic product arachidonic acid
in either tumor or serum lip~ds (5).
If you use· a ratio of linoleic acid to
arachidonic acid (A.A.) as a r01,1gh index to the degree
of c:onversion of linoleic to A.A., it is highest in low
- incidence groups and low in the high incidence groups
· (corn oil)..

Also when pure A.A. was added to the diet

of tumor bearing rats it did not produ~e a significant
increase in tumor mass (5,13).

This would imply no

direct relationship between dietary linoleic acid, A.A.
and prostaglandins.

It is possible that dietary A.A •.

does not enter the same tissue pool as A.A. synthesis
from linoleate ( 13) .
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Figure l. Biosynthesis of prostaglandin precursors from
linoleic acid. Taken from Martin (32).
7,12-dimethvlbenze[a]anthracene (DMBA)
The effects of dietary fats are strictly
promotional,

They may assist in the initiation phase

but some type-~f carcinogen must be present for the
induction of cancer.

The two commonly used methods of

induction of mammary cancer are radiation and
hydrocarpons (16) .
Polycyclic aromatic hydrocarbons (PAH) are
widely distributed in environmental pollutants that have
been linked to human tumorigenesis at a variety of
anatomic sites.

In animals, PAH are potent carcinogen!!
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(8).

In particular, the synthetic PAH, DMBA, is used to

induce tumors of the mammary gland in experimental
animals.

Although DMBA is less widely distributed in

the environment as compared to other related PAHs such
as benzo(a)pyrene,·chrysene, and fluorunthene, its
overall metabolism is similar (16).
A high incidence of testicular cancer was
observed in chimney sweeps in the early

·1s-oo 's.

It was

determined by Percivall Pott (1808) that it was due to a
carcinogen found in the soot.

After a series of

research that encompassed four countries and required a
162 years, aromatic hydrocarbons were isoiated and
synthetic forms began being produced ( 16) ·.
DMBA is one of the most potent carcinogens.
structure is shown in figure 2.

Its

Carcinogenic

hyd_rocarbons are flat molecules with conjugated double
bonds systems and usually posses substituent groups of a
special sort or an additional ring at a salient position
on the molecule (16).
There are three cancer prone areas in relation
to DMBA: (1) mammary acinar, which line the lactiferous
ducts (17), (2) hemopoietic tissue, and (3) fibroblasts
(16).

This results in several types of cancer: mammary

adenocarcinoma, mammary fibroadenoma, leukemia, and ear
duct cancer (16).

However, mammary cancer is the most

9

prevalent of the group (table l).

Figure 2.

The structure of DMBA.

Taken·from Huggins

( l 6) •

Adenocarcinomas consist of acini lined with many
layers of epithelial cells arranged to form gland like
structures with papillary projections (16).

These

tumors can arise any where in the mammary gland.

In the

·rat they have been found to occur from the neck to
perineum.

These tumors rarely metastasize and they

bring about death by attaining gigantic size and
invading adjacent tissue with consequent hemorrhage,
necrosis, and ulceration (16).
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Table l. Incidence of neoplasms in rats fed DMBA.
Taken from Huggins (16).

TUMORS

PERCENT

Mammary cancer

100

Fibroadenoma

89

Leukemia

3

Ear duct cancer

5

DMBA is taken up_by the liver metabolized and
~xcreted into the bile or exported.

Mammary tissue also

has an ability to metabolize DMBA to a limited extent.
The metabolic pathways consist primarily of oxygenation
of the methyl groups and to a small extent of the ring
structure (16).

The main products of.the metabolism of

DMBA by rat liver homogenates are the isomeric
monohydroxymethyl derivatives: 7-hydroxymethyl-12methyl-BA and 7-methyl-12-hydroxymethyl-BA.

Small

amounts of phenols, diols, epoxides, and
dihydrodihydroxy compounds as well as -7, -12-epidioxy7, 12-DMBA were detected (16).
The electrophilic intermediates of the
metabolism of DMBA are what bind to nucleophilic regions
of DNA.

The bay-region of syn- and anti-3,4-
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dihydrodiol-1,2 epoxides are considered to be the
ultimate carcinogenic forms of.DMBA (8).

These bind

covalently to deoxyadenosine and deoxyguanosine residues
of DNA (8).
It was determined in 1971 that the number one
chromosome of the rat was the most vulnerable, to DMBA
(16).

This high susceptibility to DMBA is exhibited in

late interphase and prophase (16).

In only 24 hours

after injection of DMBA one half of the cells in
metaphase in bone marrow have chromosomes with breaks
and gaps (16).
The tumors developed due to DMBA are excellent
for scientific study of breast cancer.

DMBA is not only

metabolized in a similar fashion to naturally occurring
PAHs. the superficial position of the tumors assures easy
palpations, the end point i_s sharp, and they rarely
metastasize (16).

INDOMETHACIN (IM)
Numerus laboratory and clinical studies have
demonstrated that prostagl~ndins (PG) are involved in
the initiation, development, and progression of some
malignant diseases(S,12 14 20-31).

Prostaglandin

levels in both human and experimental carcinomas are
consistently higher (19).

Recent studies in

animal
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tumor models suggest that inhibitors of arachidonic acid
(A.A.) metabolism such as indomethacin (IM) may inhibit
tumor growth (5,12,20-28) although in some studies no
antitumorigenic effects were observed (21),

IM and

other aspirin like compounds were recently studied by
Karmali and Marsh (19).

As seen in table 2, all of

these compounds resulted in a reduction of tumor growth.
Most chemopreventitive drugs have effects at one
of three stages in tumor development (figure.·3).

A.A.

metabolic inhibitors work as suppressing agents (19).
This has been demonstrated by the use of IM in several
studies (5,8,11,12,15,20,22-31), while others who had a
reduction in PGs saw no drop in tumor burden (21).

In

fact, the presence of IM in the diet has been shown to
suppress tumor growth in animals fed a high fat diet, to
1/3 the size of tumors· of high fat control rats ( 11).
It was demonstrated that IM does not effect mammary
tumor cell proliferation in vitro whereas it reduces
the growth rate of the same neoplasms in vivo (15).

It

is therefore evident that the products of A.A.
metabolism help in tumor promotion.
~

One of the products

of the pathway inhibited by indomethacin
(cyclooxygenase) are PGEs.

Their role in the bodies

immunological system warranted research to determine
their function in the relationship between a high fat

diet and mammary cancer.
IM treatment which inhibits the conversion of
A.A. to PGs; could be expected to cause an accumulation
in PG precursors in the·membrane.

This however, is not

the case, as demonstrated in a recent study by Feldman
and Hilf (21).

In addition to the direct activity of IM

on prostaglandins synthesis, this inhibitor of the
cyclooxygenase pathway can lead to increased synthetic
activity of the lipo_xygenase pathway which has products
that are reported to stimulate natural killer (NK) cell
activity (27).

The products of the lipoxygenase pathway

are leuoktrienes so named because the compounds were
first detected in leukocytes. ( 34) .

TABLE 2. Mammary tumor growth in rats treated with
cyclooxygenase inhibitors. Taken from Karmali and
Marsh (19).

Treatment

.:Tumor weight in grams

Control

2.49

Indomethacin

1.96

Ibuprofen

1.96

Flurbiprofen

1.71
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Precursor Compounds

Formation of Carcinogens

t

Carcinogenic Compounds
Blocking Agents

l

Reactions With
Cellular .Targets
Suppressing Agents

l

Neoplastic
Manifestations

FIGURE 3, Classification of chemopreventive agents.
Taken from Wattenberg (18).
Prosta·glandin E2
The major rate limiting factor for PG synthesis
is the availability of the fatty c:icid precursor (32).
Cells usually contain substantial quantities of enzymes
in the active form, but they sequester the fatty acid in
the membrane phospholipids and in cholesteroyl esters,
triacylglycerols, and lipoprotiens.

Phospholipases,

cholesterol esterases, triglycerides, lipases, and
lipoprotein lipases that catalyze hydrolysis of the
lipids can be activated by·numerus "non-specific"
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factors.

These include mechanical pressure, hypoxia,

temperature chan~es and mild trauma (32).
The activation of these enzymes stimulate the
release of a 20 carbon fatty acid, arachidonic acid,
which is metabolized into a variety of active mediators.
The initial enzymes, cyclooxygenase and lipoxygenase,
that convert A.A. to its mediators are constitutively
active within cells (33).

Thus three main groups of

derivatives- the prostaglandins, the thromboxanes, and
the leukotrienes- are formed ( 34).

Prostaglandins and

thromboxanes are formed via the cyclooxygenase pathway
(figure 4).

It is this pathway that is i~hibited by

aspirin and aspirin like drugs such as indomethacin
(IM).

These non-steroidal anti-inflammatory drugs

inhibit PGs and thromboxanes by either binding to or
covalently modifying the protein region near the heme
unit of the cyclooxygenase enzyme (35).
A cyclooxygenase enzyme binds to a cytochro~e.b-.
like hemoprotein cofactor (mw=70,000), which is readily
lost, and in addition requires a nonheme iron which
catalyzes the formation of PGG2 from A.A. (35).
Prostaglandin G2 is a highly unstable endoperoxide that
is rapidly converted to PGH2.

The cyclooxygenase also

catalyzes the second reaction, and the enzyme is
therefore known as the "prostaglandin synthetase
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system".

The cyclooxygenase additionally catalyzes its

own destruction and thereby limits PGG production after
a time.

The fate of PGG depends on the cell type.

In

most parts of the body a PGE isomerase catalyzes the
formation of PGE (32).

It is this particular PG that

cancer researchers believe to be involved in the
enhancement of cancer.
The actions of PGs are executed through specific
membrane bound receptors (36), which interact in complex
ways with other regulators.

These include cAMP, cGMP,

Ca++, calmodulin, phospholipids, neurotransmitters,
growth-promoting hormones, and kinase C (32j.
Investigators have shown that PGs, particularly of the
E-series, stimulate membrane bound adenylate cyclase in
mammary tissue, therefore elevating cAMP levels (36).
The same mechanism by which retioniods are believed to
inhibit tumor growth (37).

Thus, the concentration of

the cAMP may play a role in determining the effect
brought about.

PGEs have a ·short half life.

structurally, they have a ketone at carbon 9 and an
alcohol at position 11 (figure 5).
It has become increasingly apparent that among
human peripheral blood mononuclear cells only the
monocyte-macrophage and not T cells or B cells have the
ability ·to produce these PGs (38),

It is believed that
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Figure 4. .. Sources of arachidonate and metabolites of
the cyclooxygenase pathway. Taken from. Martin (32)
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the PGEs secreted by natural killer suppressor cells of
the monocyte-macrophage lineage inactivate natural
killer cells (23-25,38).

If this is true, host

macrophages may promote metas~asis by PG mediated
inactivation of natural killer cells (23).
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Figure S. Structure and nomenclature of the classical
prostaglandins. · Taken from Caton and Hart (36).
This suppression may have its effect at one or
all of the following steps: (l)

development of the

lytic function (activation process); (2) the recycling
function of the activated cells, and (3) the killer
function of the activated cells.

PGs have also been

demonstrated to suppress antibody formation, lymphokine
production

and T cell cytotoxici ty ( 25) ..
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There appears a strong correlation between PG
levels and metastasis.

Whatever the size of the lesion,

a high PG level was found associated with a marked
increase in axillary lymph node metastasis in human
breast cancer (26) and in animal models (27).
While T cells, activated macrophages and NK
cells have all been considered to play a role in
metastasis, the role of the latter two cell classes
appears particularly appealing because they do not
require the fine antigenic specificity or memory
response obligatory for T cell function and thus may be
able to respond to a broad spectrum of tumors and may be
more amenable to therapeutic manipulations (23).
It has recently been reported that during
development of transplanted or spontaneous tumors in
mice, the NK activity declines with increasing tumor
burden.

It appears that NK cells are inactivated not

reduced in number.
via PGs (23).

This inactivation may be mediated

Although significant inhibition of

cytotoxicity by PGs was observed in experiments a
complete suppression of NK activity was never obtained
(25).

This finding may reflect the existence of a

subpopulation of NK cells that lack PG receptors, and
are therefore resistant to PG mediated inhibition (25).
IM and its antiaggratory action would prevent
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tumor cells form sticking to the endothilial wall of the
circulatory system and as such reduce the formation of
new tumors.

In this respect it is also important to

consider the direct aggregatory of tumor cells on
platelets (by means of release of thromboxane) and on
vasoconstriction (27,39). The concept that PGs and
related metabolites of A.A. are local regulators of the
microcirculation is one that has been investigated
extensively for the past several years.

It is based on

the observations that the adminstration of locally
synthesized PGs are capable of profoundly changing
microvascular tone and various vascular beds (39).

In

this relation PGEs are vasodilators therefore it is easy
to see how PGEs could enhance metastasis.
The effect of PGs on the immune response appears
to follow a bell shaped dose response relationship.

Low

levels of PGs are required to initiate the immune
response.

This was demonstrated by the fact that adding

anti-PGE2 inhibited cell mediated immunity (21).

When

the PGE2 concentration was high it inhibited the same
response (21).

The question still remains whether it is

the absolute level of PGE or the proportional decrease
(21).

As more and more research data are brought

forward it will become more clear how PGEs and dietary
fat increase tumor growth.

Yet, some areas are still
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inconclusive.

Ho'w PGs control the immune system?

Why

dietary fat and ~he formation of A.A. are not
correlated?

How they increase metastasis?

These and

several other questions will have to be answered before
the relationship between dietary fat and mammary cancer
can be understood.
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Research Objectives

In this study young virgin female rats were fed
diets of different levels of polyunsaturated fat and
then given IM to reduce PGE levels.

Testing of the

following hypothesis was accomplished by examination of
tumor number, tumor burden, percentage of tumor bearing
rats per group, PGE2 levels, and tumor occurence.

Diet
A high level of polyunsaturated fat in the diet
and its ·relationship to mammary cancer has been observed
in several studies (4-16).

Its role in the increase of

PG levels is still being widely studied.
It was hypothesized that those animals fed a
high fat diet would show an increase in tumor number,
tumor burden, percentage of tumor bearing rats, PGE2
levels, and have a later time of occurence.

Indomethacin
This nonsteroidal anti-innlammatory agent has
not only been demonstrated to reduce PGE2 levels, but
also tumorigenesis (12-13).
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It was hypothesized that those animals given IM
would show a decrease in PGE2 levels, tumor number,
percentage of tumor bearing rats, tumor burden, tumor
size andhave a earlier time of occurence.

PGE2
The effects of PGE on the immune system of tumor
bearing rats have only recently been demonstrated (431).

These changes in the immune system would cause a

decrease in survival chances.
It was hypothesized that animals with high PGE2
levels would show an increase in tumor burden, tumor
number, percentage of tumor bearing rats and have an
earlier time of tumor occurence.

MATERIALS AND METHOD

Animal Treatment
Female Sprague-Dawley rats were obtained from
Harlen Sprague-Dawely Inc., Indianapolis, Indiana.

The

rats were housed in stainless steel cagJs with one rat
per cage in a temperature• and light controlled room.
Food and water were available ad libitum. - The rats were
assigned to one of four groups --two_experimental: IM
high fat (HFI) and IM low fat (LFI) and two control:high
fat (HF) and low fat (LF).
on either a high or low

The animals were then placed

polyunsaturated

fat ··diet

containing 20% or 4% fat diet respectively.

The common

components in both diets were in percentage by weight
and both diets were equal in calories (table 3).

The

casein,· cellulose, minerals, vitamins, methionine, and
choline were purchased from U.S. Biochemical, Cleveland,
·Ohio.

The corn oil and sugar were purchased locally .
.

IM (Sigma Chemical Company, st. Louis, MO) was dissolved
in 10 ml of ethanol and diluted with water to give a
final concentration of .025mg/ml.
At 50 days of age all animals received a single
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10mg dose of DMBA in 1ml of corn oil by intragastric
administration.

One month later all rats were being

palpated weekly.

At day 89 all of the animals were

decapitated and at the time of sacrifice blood was
collected in polypropylene tubes and clotted blood was
centrifuged at 3000xg for 10 minutes, serum was removed,
and stored at O degrees centigrade.

All of the tumors

were measured in 3 dimensions (LxWxH) with calipers.
One tumor was dissected from each tumor bearing rat,
frozen in dry ice-acetone mixture, and stored at -80
degrees centigrade.

Table 3.

Diet concentration by percentage

COMPONENT

HIGH FAT DIET

LOW FAT DIET

Casein

21.6%

21.7%

Sucrose

21.9%

57.0%

Corn oil

19.4%

3.9%

Cellulose

31.8%

12.1%

Minerals

3.8%

3.8%

Vitamins

1.0%

1.0%

Methionine

0.3%

0.3%

Choline

0.2%

0.2%
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PGE2 Extraction and Determination
Tumors were homogenized 1 _to 5 (g/ml) in Kerbs
Ringer Bicarbonate Glucose and centrifuged at 3500xg at
4 degrees centigrade.

The homogenates and plasma

samples were reduced to pH 4 with lN HCL.

The

prostaglandins were then extracted 1:10 with ethyl
acetate (39).

The samples were then dried with a vacuum

pump and resuspended 1:1 in assay buffer.

PGE2

concentrations were determined with a prostaglandin E2
[125I] RIA kit (Dupont Biomedical Products, Boston, MA).
Buffer and antiserum were· added to each sample and
incubated 24 hours.

The precipitating solution was

added and the samples were centrifuged at 2000xg at 4
degree centigrade.

The pellets were resuspended in 5ml

of Ready Safe Scintillation Fluid and read in a Beckman
Scintillation Counter model LS 801.

statistical Analysis
An un-paired t-test was used to determine the
significance of the results (P>.OS).

RESULTS AND DISCUSSION

Rats exposed to DMBA at day 50 developed tumors
89 days later on all dietary regimes (table

4).

A

lower

percentage of rats developed tumors in both LFI and LFC
when compared to their experimental groups.

The

indomethacin did not reduce the percentage of rats
developing tumors in the groups receiving ·the HF diet,
but was somewhat effective in reducing the number of
rats with tumors from 73% to 50% on low fat diets.

The

indomethacin rats also developed tumors later than their
controls (table 4).

Table 4. Comparison between groups, percentage of rats
with tumors, body weight at death, and first day of
tumor occurrence in relation to palpation schedule

GROUP

BODY WT.

PERCENTAGE

FIRST DAY OF OCCURRENCE

LFC

249

73%

76

HFC

240

82%

68

LFI

222(a)

50%

8S(b)

HFI

230(a)

91%

7l(b)

a
b

Statistically different from others, p>o.os.
Statistically different from others, p>0.05.
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A comparison of body weights at death can be
seen in table 4.

Those rats in the experimental groups

had body weights that were significantly lower.

This

could be due to IMs toxic effects in the gastric system
(4,20,23).

A study done by McCormick and Wilson

demonstrated that these effects can be counteracted by
certain antioxidants like butlyated hydroxytolune (20).
Total tumor number per dietary group and tumor
number per rat were reduced in the LFC and LFI groups
(table 5).

Tumor number per tumor bearing rat was lower

only in the LFC group (table 5).

The data presented in

tables 4 and 5 disagree with the hypothesis statement
that the effects of indomethacin would be demonstrated
equally in both experimental groups.

Its effects were

more profound in the low fat group.
A distinct difference can be seen in
relationship to type of diet, total tumor burden, and
average tumor burden per rat (figures 6 and 7).

In both

cases the low fat diets were lower, which agrees with
the hypothesis that the low fat diet will reduce
tumorigenesis at all phases of the study.

The

comparisons between the control groups and the
experimental groups were not significant, but the
experimental groups were somewhat higher.
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Table 5. Comparison between groups, total tumors, tumor
number per rat and tumor number per tumor bearing rat.

GROUP

a

TOTAL
TUMORS

TUMOR ii
PER RAT

TUMOR ii PER
TUMOR BEARING RAT

LFC

ll(a)

1

1.4

HFC

23

2.1

2.5

LFI

15(a)

1.3

2.5

HFI

21

1. 9

2.1

statistically different from high fat diet, p>0.05.
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Figure 6, Total tumor burden per group.
Showing a
significant difference between the two diets, p>0.05.
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Average tumor burden per rat.

Showing a

significant difference between the two diets, p>0.05.
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The PGE2 assay was inconclusive.

Yet, certain

trends could be see_n in the average no.rmalized percent
of PGE2 [Il25] bound.

Since the assay required the use

of a competitive binding, a inverse relationship exists
between percent bound and PGE2 levels.

Thus, the higher

the level of PGE2 [Il25] bound the lower the
concentration of PGE2 in the sample (table 6).

In the

plasma samples the LFC group had higher PG levels than
the LFI group.

A similar tend could be seen in the

comparison of the HFC and HFI groups.

The PGE2

concentrations in the tumors appeared higher than those
in the plasma samples but this could be due to a
discrepancy in protocol.

The same trends were observed

in relation to experimental and control groups as seen
in the plasma samples. IM was again successful in the
reduction of PGE2 levels.
In summary, the low fat diet reduced the
percentage of tumor bearing rats, deterred tumor
formation by a number of days, reduced the total tumors
per group and per rat, and lowered the tumor burden
(tables 4 and 5, figures 6 and 7 ) •

These reductions may

have been brought about by the effects of lower PGE2
levels in those rats fed a low fat diet ( table 6) .
IM treatment also deterred tumor formation,
decreased the percentage of tumor bearing rats, and
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lowered animal body weights at death (table 4).

This

treatment had no significant effect on total tumor
numbers or tumor burden (table 5, figures 6 and 7).

Table 6.

Normalized percent bound of PGE2 [Il25]

SAMPLE

LFC

. HFC

TUMORS

5.5

4.7

10.7(a)

6.4

PLASMA

21.8

13.4

35.0(b)

16.4

a
b

LFI

HFI

Statistically different from the other groups, p>.05.
statistically different from the other groups, p>.05.
Therefore, it was demonstrated that

indomethacin reduces the number of tumor bearing rats,
but does not reduce the size of the tumors which do
occur.

A study on human breast cancer and PG

concentration indicated that PG production was higher in
small tumors and in tumors with a high cellular density
(26).

That was not demonstrated in. this study.

The LFC

group had lower tumor number per tumor bearing rat
(figure 6) and lower average tumor volume (figure 7)
than the HFC, but the LFC tumor PGE2 levels were lower.
It would be interesting to see the influence of
anti-inflammatory steroids on DMBA induced mammary
tumors.

These steroids act by inhibiting the release of

34

A.A., they prevent formation not only of PGs and
thromboxanes, but also leukotrienes (34).
Corticosteriods have side effects, but a new dual 5lipooxygenase/cyclooxygenase inhibitor "L-652,343" is
being studied for use in hypersensitivity disorders,
does not (41).

The outcome of a study using this new

molecule and mammary cancer would give an answer to the
question of the role of lipoxygenase pathway in this
type of cancer.
In the battle, to determine the concentration at
which PGEs initiate or deter the immune system, PGE
agonist like 16-dimethyl PGE2 could be used (42,43),
while the role of leukotrienes could be determined by
using there antagonist and agonist (44). Experiments
using these molecules would help define the roles of
PGEs and leukotrienes in the relationship between a high
fat diet and mammary cancer
Although a large amount of research has been
performed linking PGE2 and mammary cancer it will
require several more years before the true mechanism, by
which PGE2 and dietary polyunsaturated fat cause mammary
cancer, will be completely understood.

Until that time

IM will probably be widely used as a chemopreventative
drug either by itself or in combination therapy.

It is

not completely known if the drug works via PG reduction
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or increasing the levels of leukotrienes, but what is
important to cancer research is the IM reduces
tumorigenesis in relation to certain types of diet,
particular~y a diet low in polyunsaturated fatty acids
as demonstrated here.
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